mk 767 has been researched along with tivozanib in 1 studies
| Studies (mk 767) | Trials (mk 767) | Recent Studies (post-2010) (mk 767) | Studies (tivozanib) | Trials (tivozanib) | Recent Studies (post-2010) (tivozanib) |
|---|---|---|---|---|---|
| 32 | 0 | 10 | 105 | 23 | 100 |
| Protein | Taxonomy | mk 767 (IC50) | tivozanib (IC50) |
|---|---|---|---|
| Epidermal growth factor receptor | Homo sapiens (human) | 0.0709 | |
| Fibroblast growth factor 2 | Homo sapiens (human) | 0.0709 | |
| Platelet-derived growth factor receptor beta | Homo sapiens (human) | 0.0709 | |
| Platelet-derived growth factor receptor alpha | Homo sapiens (human) | 0.0023 | |
| Vascular endothelial growth factor receptor 1 | Homo sapiens (human) | 0.0032 | |
| Ephrin type-B receptor 2 | Homo sapiens (human) | 0.0175 | |
| Vascular endothelial growth factor receptor 3 | Homo sapiens (human) | 0.0017 | |
| Vascular endothelial growth factor receptor 2 | Homo sapiens (human) | 0.0783 | |
| Broad substrate specificity ATP-binding cassette transporter ABCG2 | Homo sapiens (human) | 0.07 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Davis, MI; Khan, J; Li, SQ; Patel, PR; Shen, M; Sun, H; Thomas, CJ | 1 |
1 other study(ies) available for mk 767 and tivozanib
| Article | Year |
|---|---|
Identification of potent Yes1 kinase inhibitors using a library screening approach.
Topics: Binding Sites; Cell Line; Cell Survival; Drug Design; Humans; Hydrogen Bonding; Molecular Docking Simulation; Protein Kinase Inhibitors; Protein Structure, Tertiary; Proto-Oncogene Proteins c-yes; Small Molecule Libraries; Structure-Activity Relationship | 2013 |